Trial Profile

A Phase 1 trial of ARV-102 analyzing safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ARV 102 (Primary)
Indications Parkinson's disease; Progressive supranuclear palsy
Focus Adverse reactions; First in man

Most Recent Events

04 Apr 2025 According to an Arvinas media release, data were presented at AD/PD™ 2025.
04 Apr 2025 Results presented in the Arvinas Media Release.
27 Mar 2025 According to an Arvinas media release, data from the first-in-human study evaluating single-ascending and multiple-ascending doses in healthy volunteers of ARV-102 will be presented at the International Conference on Alzheimers and Parkinsons Diseases (AD/PD™), April 1-5, 2025 in Vienna, Austria.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com